RVMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Revolution Medicines Inc (RVMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The strong analyst ratings, positive price target revisions, and upcoming catalysts in oncology trials make this stock a solid long-term opportunity despite current technical weakness.
The MACD histogram is negative (-0.663) and expanding, indicating bearish momentum. RSI is at 24.581, suggesting the stock is nearing oversold territory. Key support is at $96.131, and resistance is at $103.217. Current price ($95.99 pre-market) is near support, indicating a potential entry point for long-term investors.
Multiple analysts have raised price targets significantly, with UBS setting a target of $145 and others ranging from $115 to $
Positive sentiment around upcoming Phase III 2L PDAC readout with a high probability of success (70%-80%).
Strong late-stage oncology pipeline with eight registrational trials in progress.
Potential M&A activity as noted by Oppenheimer.
Recent technical indicators show bearish momentum.
Revenue remains at $0, and the company is not yet profitable, with a net income of -$364.89M in Q4
No recent news or congress trading data to provide additional confidence.
In Q4 2025, the company reported a net income loss of $364.89M, which improved by 87.54% YoY. EPS also improved to -1.88, up 67.86% YoY. However, revenue remains at $0, and gross margin is 0%, reflecting the company's pre-revenue stage.
Analyst sentiment is overwhelmingly positive, with multiple Buy and Overweight ratings. Price targets have been raised significantly, with the highest at $150. Analysts highlight the company's high-quality oncology pipeline and upcoming pivotal data readouts as key drivers for growth.
